1)厚生労働省.令和2(2020)年人口動態統計月報年計
2)日本循環器学会.2019年(2020年度実施・公表)循環器疾患診療実態調査報告書
3)厚生労働省.令和元(2019)年度国民医療費の概況
4)Murtagh G, Dawkins IR, O' Connell R, et al. Screening to prevent heart failure(STOP-HF) : expanding the focus beyond asymptomatic left ventricular systolic dysfunction. Eur J Heat Fail 2012 ; 14 : 480-6.
5)国立がん研究センター.がん情報サービス https://ganjoho.jp/public/index.html
6)S Yusuf, Pitt B, Davis CE, et al. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992 ; 327 : 685-91.
7)Jong P, Yusuf S, Rousseau MF, et al. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction : a follow-up study. Lancet 2003 ; 361 : 1843-8.
8)Lupón J, Gavidia-Bovadilla G, Ferrer E, et al. Dynamic Trajectories of Left Ventricular Ejection Fraction in Heart Failure. J Am Coll Cardiol 2018 ; 72 : 591-601.
9)Baker DW. Prevention of heart failure. J Card Fail 2002 ; 8 : 333-46.
10)Nakamura M, Tanaka F, Sato K, et al. B-type natriuretic peptide testing for structural heart disease screening : a general population-based study. J Card Fail 2005 ; 11 : 705-12.
11)Ledwidge M, Gallagher J, Conlon C, et al. Natriuretic peptide-based screening and collaborative care for heart failure : the STOP-HF randomized trial. JAMA 2013 ; 310 : 66-74.